Moderna: 2025 Contrarian Play
Portfolio Pulse from
Moderna, a Nasdaq-100 stock, ended 2024 as one of the worst performers but is seen as a contrarian play for 2025 due to potential vaccine catalysts. Despite a $15 billion market cap and $3+ billion in revenue, concerns about spending persist. However, its CMV and cancer vaccines could boost sales.
December 31, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's stock is down to $40, making it one of the worst-performing Nasdaq-100 stocks in 2024. However, it presents a contrarian opportunity for 2025 due to potential sales boosts from its CMV and cancer vaccines.
Moderna's current low stock price and market cap, combined with its promising vaccine pipeline, suggest potential for growth. The CMV and cancer vaccines are key catalysts that could drive sales and justify R&D expenses, making it a contrarian play.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100